VenturesTaihoAbout
Taiho Ventures is the corporate venture arm of a $400M Japanese specialty pharmaceutical company, deploying into oncology, immunology, and platform biology since 2016. The pages of this site are the public face of a register that lives in an annual letter; the paragraphs below are the part of that register the brand is willing to say out loud.
Taiho Ventures, LLC
Taiho Ventures, LLC is the corporate venture arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy and immunology, and urology. With $400M under management, we are actively investing in early-stage private companies strategically relevant to Taiho Pharmaceutical. We consider company creation, spinouts, and the option-type of investments as well as pure equity investments.
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharmaceutical company focusing on the three fields of oncology, allergies and immunology, and urology.
We strive to improve human health and contribute to a society enriched by smiles.
In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan that develops innovative medicines for the treatment of cancer. The company creates quality products that effectively treat a variety of medical conditions in other areas as well. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people’s efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, visit taiho.co.jp/en.
The mandate, in three
The therapeutic areas Taiho Pharmaceutical has commercialized in for sixty years. We invest where our parent has clinical, regulatory, and commercial muscle — not where the deck looks good.
Most rounds close on a term sheet. A few close on a thesis about who the founder wants on the cap table ten years from now. We are usually in the second category, and often the third or fourth name on the wire.
Joint diligence with Taiho Pharmaceutical on clinical-stage investments. The result is a Series A or B board with American venture firms and a Japanese pharmaceutical company in the same room, before the round closes.
Contact
The mandate is the filter; the cap table is the seat. If a round fits the filter, the seat is the conversation.